We identified a human orthologue of tRNA:m 5 C methyltransferase from Saccharomyces cerevisiae, which has been previously shown to catalyse the specific modification of C 34 in the intron-containing yeast pre-tRNA C 34 formation depends on the nucleotide sequence surrounding the wobble cytidine and on the structure of the prolongated anticodon stem. Expression of the human Trm4 (hTrm4) cDNA in yeast partially complements the lack of the endogenous Trm4p enzyme. The yeast extract prepared from the strain deprived of the endogenous TRM4 gene and transformed with hTrm4 cDNA exhibits the same activity and substrate specificity toward human pre-tRNA Leu transcripts as the HeLa extract. The hTrm4 MTase has a much narrower specificity against the yeast substrates than its yeast orthologue: human enzyme is not able to form m 5 C at positions 48 and 49 of human and yeast tRNA precursors. To our knowledge, this is the first report showing intron-dependent methylation of human pre-tRNA
Leu
ðCAAÞ genes as substrates, we have shown that m 5 C 34 is introduced only in the intron-containing tRNA precursors when the substrates were incubated in the HeLa extract. m 5 C 34 formation depends on the nucleotide sequence surrounding the wobble cytidine and on the structure of the prolongated anticodon stem. Expression of the human Trm4 (hTrm4) cDNA in yeast partially complements the lack of the endogenous Trm4p enzyme. The yeast extract prepared from the strain deprived of the endogenous TRM4 gene and transformed with hTrm4 cDNA exhibits the same activity and substrate specificity toward human pre-tRNA Leu transcripts as the HeLa extract. The hTrm4 MTase has a much narrower specificity against the yeast substrates than its yeast orthologue: human enzyme is not able to form m 5 C at positions 48 and 49 of human and yeast tRNA precursors. To our knowledge, this is the first report showing intron-dependent methylation of human pre-tRNA
INTRODUCTION
Maturation of eukaryotic cytoplasmic tRNAs is a multistage process that includes the processing of 5 0 and 3 0 ends, intron splicing in the case of intron-containing pre-tRNAs, transport from the nucleus to the cytoplasm and numerous nucleoside modifications that take place both in the nucleus and in the cytoplasm. Three classes of intron-containing tRNA genes are present in the human nuclear genome: tRNA . In all cases, introns are located one nucleotide downstream from the anticodon, which is a typical feature of nuclear intron-containing tRNA genes.
In the case of tRNA Tyr ðGYAÞ genes, it has been shown that the introduction of pseudouridine in the middle position of the anticodon (Y 35 ) is intron dependent in yeast, plants, animals and humans (1) (2) (3) . Moreover, it has been demonstrated that the introduction of Y 35 strictly depends on the nucleotide sequence surrounding the U 35 to be modified and depends rather on the length of the intron than on its structure (4). Transfer RNA Leu ðCAAÞ genes contain introns in yeast and vertebrates (5, 6) . However, in plants, there are no introns in these genes (7) . The first position of the yeast anticodon sequence-cytosine-in tRNA Leu ðCAAÞ is methylated to 5-methylcytosine (m 5 C) 34 . In yeast, this methylation is intron dependent and its introduction strictly depends on the intron structure (5) .
The first functional evidence of the importance of Y 35 in tRNA Tyr and m 5 C 34 in tRNA Leu came from the Abelson laboratory (1, 5) . The construction of mutant yeast tRNA 
and tRNA
Leu genes without introns resulted in the production of mature tRNA molecules without appropriate modified bases. When the suppressor activity of a tRNA Tyr product derived from intron-containing tRNA (SUP 6 coding for ochre suppressor tRNA) with the ochre suppressor tRNA transcribed from the gene without intron was compared, it turned out that tRNA Tyr derived from the mutated gene without intron exhibited a strong reduction in the suppressor activity. In an analogous experiment, a mutant, intron-less yeast tRNA Leu gene encoding amber suppressor tRNA (SUP 53) also gave a product with a weak suppressor activity when compared with the intron-containing amber tRNA Leu suppressor gene product. In both cases, the decreased suppressor activity correlated with the absence of Y 35 and m 5 C 34 , respectively. Similarly, Y 35 is required in the anticodon (GYA) of cytoplasmic tRNA Tyr from Nicotiana rustica for UAG and UAA suppression in the translation of the tobacco mosaic virus (TMV) RNA (8) . Summarizing the afore-mentioned experiments, it is clear that both Y 35 and m 5 C 34 are necessary to stabilize anticodon-codon pairing leading to the correct decoding of mRNA. In this paper, we show that intron in the human pre-tRNA Leu ðCAAÞ is indispensable for the C5-methylation of cytosine in the first position of the anticodon. We also show that the modification of C 34 depends on the nucleotide sequence surrounding the position to be modified and on the structure of intron-containing prolongated anticodon stem.
Enzymes that introduce Y 35 and m 5 C 34 in the introncontaining pre-tRNA Tyr and pre-tRNA Leu , respectively, have been identified in yeast (9, 10) . However, our knowledge about the corresponding enzymes in multicellular eukaryotes remains obscure. The first human m 5 C methylase Dnmt2 has been reported very recently and is responsible for the modification of C 38 in tRNA Asp in mice, Drosophila melanogaster and Arabidopsis thaliana. This MTase was found to be localized in cytoplasm and acts at the level of a mature tRNA molecule (11) . Here, we present the characterization of a human gene encoding a methyltransferase (MTase) that is involved in the formation of m 5 C 34 in tRNA Leu ðCAAÞ . The product of the gene, hTrm4, acts at the level of the introncontaining tRNA precursor and is localized in the nucleoplasm and nucleolus. During the preparation of this paper, it was found that this MTase is a novel downstream Myctarget which mediates Myc-induced cell proliferation and growth. Therefore, the characterization of hTrm4 substrate specificity can be essential since this MTase is a potential target for cancer therapies (12) .
MATERIALS AND METHODS

Enzymes and reagents
The restriction enzymes, T4 DNA polymerase and T4 DNA ligase were from Roche, Fermentas and Promega. RNase T 2 and SAM (S-adenosyl-L-methionine) were obtained from Sigma. [ 32 P]GTP. Transcripts were purified on 10% denaturating polyacrylamide gels, identified by autoradiography, excised from the gels and eluted with 0.3 M sodium acetate (pH 5.2), 0.5 M EDTA, 0.1% (w/w) SDS. After phenol/chloroform extraction and ethanol precipitation, the RNA was resuspended in water. The average amount of the recovered labelled tRNA transcripts varied between 1 and 2 pmol per reaction. The transcription of mini-helix was performed as described in (14, 15) .
In vitro 5-methylcytosine formation assays in HeLa and yeast extract A nuclear cell-free extract was prepared from HeLa cells according to Dignam et al. (16) . Yeast cells used for protein extract preparations were grown as follows: single yeast colony was picked from YPD agar plate and inoculated into 15 ml SD-U synthetic medium containing 0.67% nitrogen base, 2% glucose, amino acids and no uracil. The culture was grown overnight at 30 C with shaking. The OD 600 of the overnight culture was determined and the amount of culture necessary to obtain an OD 600 of 0.4 in 50 ml of induction medium was calculated and taken for further experiments. Cells were pelleted at 1500 g for 5 min at 4 C, resuspended in 2 ml of induction medium (SD-U medium containing 2% galactose instead of 2% glucose), inoculated into 50 ml of the induction medium and grown overnight at 30 C with shaking. Yeast S-10 extract was prepared by the following procedure: 5 ml of cell suspension were centrifuged, collected, washed twice in 500 ml of distilled water and resuspended in twice their volume of lysis buffer [50 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.1 mM EDTA, 10 mM MgCl 2 , 10% glycerol, 2% Protease Inhibitor Cocktail for yeast (Sigma)]. One volume of glass beads was added. The mixture was frozen in liquid nitrogen and thawed at room temperature. The suspension was vigorously vortexed 5-7 times for 1 min with 5 min pause between each vortexing when the suspension was kept on ice. The resulting homogenate was centrifuged at 12 000 g for 20 min to remove cell debris. The resulting supernatant was aliquoted, quickly frozen in liquid nitrogen and kept frozen at À70 C for later use.
Quantification of m 5 C 34 in pre-tRNA (CAA)
Leu
About 3000 c.p.m. of 32 P-labelled RNAs, obtained as described above, were digested with 0.5 U of RNase T 2 for 5 h at 37 C in 10 ml of 5 mM ammonium acetate, pH 4.6. The labelled nucleotides were identified by a twodimensional (2D) chromatographic analysis on cellulose TLC plates as described by Grosjean et al. (17) . The efficiency of m 5 C 34 formation was measured by cutting out the labelled spots from the TLC plates and counting the radioactivity by the liquid scintillation technique. Otherwise, radioactivity in the spots was evaluated by ImageQuant 5.1 software after exposure to a PhosphorImager screen (Typhoon, Molecular Dynamics, USA) and scanning. Taking into account the amount of label in each of the nucleotide spots (AMP, UMP, GMP, CMP and/or m 5 CMP) and knowing the relative number of labelled nucleotides per RNA substrate, the number of moles of m 5 C per mole of pre-tRNA was easily calculated.
Cloning of yeast and human TRM4 cDNA
Yeast Trm4 protein was used as a query in searching for sequences of homologous proteins in the human expressed sequence tags (ESTs) database using tBLASTn (18) . For the localization of the gene in human genome and the determination of the chromosomal localization, BLAT software was used.
hTrm4 cDNA was amplified from the human cDNA library using following primers: 5 0 -ATGGTGGTCAACCATGAT-GCCTCCAGCATAC-3 0 and 5 0 -TCACCGGGGTGGATGG-ACCCCCGCCGG-3 0 . PCR was performed in two step 'touchdown' manner, with the following conditions: 30 s at 96 C, followed by 25 cycles of 5 s at 96 C and 4 min at 72
C. The PCR product of expected size was excised from the agarose gel and eluted. The cDNA product was re-amplified with primers harbouring sequences for XbaI and EcoRI restriction enzymes and cloned into the pUC-19 vector (giving hTRM4/pUC construct) and sequenced. Yeast genomic DNA was isolated using QIAGEN Genomic DNA kit according to manufacturer's instructions. Primers used for the amplification of yeast Trm4p cDNA were: 5 0 -AAAGGATCCACCATGGCTAGAAGAAAGAATTTCAA-3 0 (Kozak translation initiation sequence is marked in italics, start codon is underlined and the BamHI restriction site is in boldface) and 5 0 -AAAGAATTCTCAATTAGCAG-CGCTAGGAG-3 0 (the stop codon is underlined and EcoRI restriction sequence is in boldface). After amplification, a product of expected size was excised and eluted from the EtBr/agarose gel. Yeast and human TRM4 cDNA were cloned into pYES2 yeast expression vector (constructs TRM4/pYES2 and hTRM4/pYES2, respectively). After each cloning procedure, the correctness of insert-vector ligation was assessed by sequencing or restriction digestion.
Yeast cells transformation
Yeast strain DYBL024w was made competent by lithium acetate/PEG 3350 treatment according to procedures described in the User Manual for pYES2 vector system (Invitrogen). Competent cells were then transformed by purified pYES2 plasmid or its derivative constructs carrying the sequence corresponding to the yeast TRM4 gene or human TRM4 cDNA, respectively. Transformed yeast cells were grown on a synthetic selective medium as required to maintain plasmids.
Preparation of low-molecular weight RNA from S.cerevisiae
Yeast RNA was extracted as described in (19) . RNA products were purified on 8% denaturing polyacrylamide gel. After EtBr staining, bands corresponding to approximate tRNA size (80-110 nt) were eluted from the gel, ethanol precipitated, carefully washed with ethanol/water (70:30), resuspended in DEPC-treated water and kept frozen at À70 C for later use.
HPLC chromatography
Low-molecular RNA (10-20 mg) was digested by P1 nuclease according to the manufacturer's manual (Roche). Nucleotides were dephosphorylated by CIAP phosphatase. The volume of the reaction was reduced to 10 ml by vacuum centrifugation. HPLC separation was performed on the reversed phase SUPELCOSILÔ LC-318 HPLC Column, 25 cm · 4.6 mm (Supelco) attached to Ä KTAexplorer 10S (Amersham Pharmacia Biotech). Chromatographic solvents were as follows: (A) 100 mM ammonium acetate and (B) 100% acetonitrile. HPLC conditions were: 4 C, 1 ml/min flow rate and absorbance measuring at l ¼ 277 nm. The gradient method consisted of 2 CV (Column Volume) solvent A, a gradient >10 CV to 6% solvent B, held 2 CV solvent B and column re-equilibration. To determine retention times of standards, 10 ml mix of six ribonucleosides (pseudouridine, cytidine, uridine, 5-methylcytidine, guanosine and adenosine), each at the concentration of 1 mM, was separated. Figure 1b) were transcribed in vitro using T7 RNA polymerase and [5 0 -a 32 P]ATP. Radiolabelled transcripts were then incubated in the presence of nuclear, cell-free HeLa extract which contained the activity necessary for m 5 C synthesis. The modified transcripts were gel-purified and analysed for their m 5 C content after a complete hydrolysis of RNA with RNase T 2 . Since RNase T 2 produces nucleoside-3 0 -monophosphates, the labelled phosphate is exclusively derived from the nearest adenosine. This ensures that only five cytidine nucleotides will be labelled in the tRNA Leu without intron and six in the intron-containing precursor (Figure 1 ), since they have 3 0 -flanking adenosines. The only m 5 C that was found in the sequenced human tRNA Leu ðCAAÞ was C 48 , but this nucleoside is accompanied at the 3 0 side by guanosine and thus C 48 is not labelled (21) . Nucleotides were resolved in a thin-layer two-dimensional chromatographic system that separates modified nucleotides from their unmodified counterparts. Figure 2 shows the autoradiograms of T 2 hydrolysates derived from intron-less and intron-containing pre-tRNA Leu . Only pre-tRNA containing intron gives rise to 3 0 -m 5 CMP (Figure 2a and b). It shows that the only cytosine that can be methylated in the introncontaining pre-tRNA Leu is C 34 . Thus, the first cytosine of the anticodon of human pre-tRNA Leu ðCAAÞ is methylated in intron-dependent manner.
The structure of a prolongated anticodon stem and nucleotide sequence that surrounds the position to be modified are crucial for m 5 C 34 formation in pre-tRNA (CAA)
Leu
To learn more about the sequence and structure specificity of m 5 C 34 methylation in tRNA Leu precursor, a number of mutants were generated where wild-type nucleotides occupying positions 32, 33, 35, 36 and 37 were exchanged for other nucleotides. Moreover, two mutants were constructed with partially deleted intron sequences (Figure 1c and d) and four mutants in which either the base-pairing in the prolongated anticodon stem was disrupted or base pairs were reversed. All mutant pre-tRNAs listed in Table 1 were examined for their capacity to be substrates for m 5 C 34 formation in HeLa cell-free nuclear extract.
A mini-helix consisting of prolongated anticodon stem was not methylated at the C 34 position. The removal of the intron arm I or II resulted in the complete abolishment of C 34 methylation. Thus, m 5 C 34 formation depends on the structure of the intron-containing prolongated anticodon stem. The exchange of C 32 to A or U had no major effect on the efficiency of m 5 C 34 formation (85% of the wild-type efficiency). However, the exchange of C 32 to G resulted in the inhibition of m 5 C 34 methylation. The transversion of U 33 to A did not significantly influence the formation of m 5 C 34 . However, the transversion of U 33 to G and transition to C strongly reduced the level of m 5 C 34 formation. All mutations in positions 35, 36 and 37 resulted in m 5 C 34 -deficient pre-tRNAs Leu . From these experiments, a consensus sequence for m 5 C 34 methylation in pre-tRNA Leu was established: C/A/ U 32 -U/A 33 -C 34 -A 35 -A 36 -G 37 . Careful inspection of the prolongated anticodon stem secondary structure reveals that A 35 , A 36 and G 37 can base pair with intron nucleotides U i11 U i10 and C i9 , respectively. To learn more about the sequence and structure dependence of m 5 C 34 methylation within the prolongated anticodon stem, additional mutations were introduced in which potential base pairs were reversed or base-pairing was disrupted. The reversion of base pair A 35 -U i11 to U 35 -A i11 did not promote m 5 C 34 formation. The reversion of base pair A 36 -U i10 to G 36 -C i10 resulted in 85% efficiency of m 5 C 34 formation, showing that no A 36 per se is indispensable for modification but N 36 -N i10 basepairing within the moiety of the prolongated anticodon stem is crucial. However, like in the case of the base pair A 35 -U i11 , the reversion of G 37 -C i9 to C 37 -G i9 resulted in a complete abolishment of m 5 C 34 formation. In this case, not the basepairing but the identity of guanosine in position 37 (and adenosine in the position 35), and possibly their pairing with C i9 and U i10 , respectively, is crucial for the modification to occur. Disruption of all three base pairs A 36 -U i11 , A 37 -U i10 , and G 37 -C i9 by the introduction of noncomplementary nucleotides within the intron sequence, i.e. A i11 , A i10 and G i9 , leads to the inhibition of m 5 C 34 formation. Thus, both the sequence and structure of the prolongated anticodon stem are crucial for the introduction of methyl group on C 34 of pre-tRNA Leu . 
NSUN2 encodes yeast TRM4 orthologue
The BLAST similarity search of human UniGene database at NCBI (22) Since our efforts to overexpress the hTrm4 protein in different prokaryotic expression systems were unsuccessful (data not shown), we decided to investigate hTrm4 activity in yeast strain BY4742 with the deleted endogenous TRM4 gene. The deletion of this gene has no phenotypic effect on cell growth (27) . Dtrm4 yeast strain BY4742 was transformed with hTrm4 cDNA that was cloned into yeast pYES2 plasmid. The same yeast strain was also transformed with pYES2 plasmid containing yeast Trm4p cDNA. Lowmolecular weight RNA was isolated from both yeast lines, digested with P1 nuclease and digestion products were dephosphorylated. Nucleosides were separated on HPLC chromatography using RPC18 column. Figure 3 presents the chromatographic elution profiles of nucleosides from yeast lines: wild type, Dtrm4, Dtrm4 transformed with plasmid carrying hTrm4 cDNA and Dtrm4 transformed with plasmid carrying yeast Trm4p cDNA. In the elution profile of nucleosides obtained from low-molecular weight RNA from Dtrm4 + yeast Trm4p, the level of m 5 C was restored to that achieved for m 5 C for wild-type yeast strain. In the Dtrm4 yeast strain, m 5 C nucleosides are undetectable. In the case of Dtrm4 + hTrm4 cDNA, we observed only a low level of m 5 C. However, this small peak appeared repeatedly in all consecutive experiments. The low level of m 5 C methylation may be due to several (mutually not exclusive) reasons: (i) hTrm4 protein recognizes a small group of substrates that are normally methylated by the yeast Trm4p enzyme, (ii) the expressed hTrm4 enzyme has only residual activity, e.g. because of non-native folding or post-translational modification or (iii) hTrm4 localization in yeast is not fully correct. To test whether hTrm4 exhibits activity toward human pre-tRNA Leu ðCAAÞ containing intron, we prepared total protein extracts from Dtrm4, Dtrm4 + hTrm4 cDNA, Dtrm4 + Trm4p cDNA and wild-type yeast lines, and conducted activity tests similar to those in the HeLa cell-free nuclear extract. Figure 4 shows the m 5 C 34 analyses of (Figure 4d ). In the case of the wild-type yeast strain, human pre-tRNA Leu containing intron is a substrate for endogenous MTase while pre-tRNA Leu without intron is not. When the protein extract from Dtrm4 yeast line was used, there was no m 5 C in intron-containing and intron-less pre-tRNAs. However, when we used the protein extract prepared from Dtrm4 + Trm4p cDNA, human introncontaining pre-tRNA Leu was methylated at C 34 , demonstrating that in the wild-type yeast strain TRM4 MTase was responsible for m 5 C 34 formation. In the case of Dtrm4 + hTrm4 cDNA, human pre-tRNA in different yeast tRNAs. Using total protein extracts from yeast lines described in the preceding chapter, we examined hTrm4 ability to methylate cytosines at positions 48/49. hTrm4 is not able to introduce a methyl group at position C 48 of human tRNA Leu , both at the level of intron-containing and intron-less precursors (Figure 6a ), while the yeast Trm4p methylates human intron-less precursor and does not recognize intron-containing substrate (Figure 6b) (Figure 6c and d) . Control experiments carried out in the Dtrm4 strain show no detection of m 5 C 48/49 formation in any tRNA tested (data not shown). Thus, human Trm4 substrate specificity is narrower than in the case of its yeast orthologue.
DISCUSSION
In this article, we describe the identification, cloning and enzyme activity of the corresponding gene product encoding human Trm4 enzyme. This is the first report showing introndependent methylation of human pre-tRNA Leu ðCAAÞ and identification of human gene encoding tRNA methylase responsible for this reaction. The hTRM4 gene was identified on the basis of its amino acid sequence similarity to a known Trm4p MTase from yeast. Our studies provide experimental validation of the phylogenetic analysis of RNA:m 5 C MTases by Bujnicki et al. who predicted the product of the NSUN2 gene as the closest human homologue of yeast Trm4p (24) . hTRM4 is a single-copy gene, located on the human chromosome 5, with the precise position 5p15.31. The hTrm4 protein is a member of an evolutionarily conserved family, which includes genuine and putative RNA:m 5 C MTases from all three domains of life, such as the human nucleolar proliferation-associated antigen p120 (NOL1) and its homologues. Wu et al. (27) reported that the yeast Trm4p was found to be localized in the nucleus, including the nucleolus, and was concentrated at the nuclear periphery. Our experiments have shown that its human homologue hTrm4 is always localized in the nucleoplasm and in nucleoli of HeLa cells, and in several cases we also observed a concentration of hTrm4 at the nuclear periphery (data not shown). These data have been recently confirmed by Frye and Watt (12) .
The presence of an intron is required for the m 5 C 34 formation in human pre-tRNA Leu ðCAAÞ as demonstrated in this paper by the maturation of intron-less and intron-containing tRNA precursor in HeLa cell-free nuclear extract. In earlier studies, Harada et al. (21) showed that this position in the mature human tRNA Leu ðCAAÞ is occupied by a hypermodified derivative. The authors suggest that this is a 2 0 -O-methylated and further hypermodified cytidine derivative (21) . Very similar results were obtained by Randerath et al. (28) when leucine tRNAs were isolated and sequenced from rat tumour, Morris hepatoma 5123D cells. Our studies show that the first stage of C 34 modification process in HeLa cells is the m 5 C 34 formation. However, the final chemical structure of this modification remains to be characterized. In addition to intron-dependent m 5 C 34 formation, we have shown that the activity of hTrm4 strictly depends on a specific sequence surrounding the cytosine to be modified and on the intron structure. Similar results were obtained studying the yeast Trm4p enzyme by Storbel and Abelson (5). However, our experiments have shown that minisubstrate composed of the anticodon stem-loop extended by the intron was not methylated at C 34 . In contrast, Motorin and Grosjean (10) presented data that analogous minihelix of yeast tRNA C in low-molecular RNA molecules was restored to that of the wild-type yeast strain (see Figure 3) . However, in the Dtrm4 + hTrm4 cDNA strain, the level of m 5 C was hardly detectable. It clearly shows that human enzyme is not able to recognize the majority of yeast tRNA substrates. Since our experiments show that yeast and human Trm4 MTases both recognize mammalian pre-tRNA Leu ðCAAÞ containing intron, the conclusion can be drawn that the yeast enzyme has much broader substrate specificity than the human Trm4. We confirm this statement showing that hTrm4 is not able to introduce m 5 C 48 at the level of intron-containing and intron-less human pre-tRNA Leu precursor. Moreover, we show that it does not methylate different yeast tRNA precursors at positions 48 and 49. In the light of these observations, it is interesting to note that Bujnicki et al. (24) identified two additional human putative orthologues of yeast Trm4p, which have probably originated from duplications and subsequent functional specializations of the original TRM4 gene in the animal lineage. One or both of these so-far uncharacterized genes may be responsible for some of the methylations carried out by the yeast Trm4p, but not exhibited by its human counterpart. This speculation can explain a very low level of m 5 C in the Dtrm4 + hTrm4 strain. Summarizing our results concerning the hTrm4 enzyme, it can be concluded that the enzyme acts on introncontaining tRNA Leu ðCAAÞ precursors, it is more sensitive to the nucleotide sequence that surrounds the position to be modified than its yeast homologue Trm4p and it is equally sensitive to the anticodon prolongated, intron-containing structure. Moreover, its sensitivity to substrate specificity is more constrained than in the case of yeast homologue-Trm4p. 
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